Clinical Trials
7
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- NoNO Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT06403267
- Locations
- 🇨🇦
University of Calgary - Foothills Medical Centre, Calgary, Alberta, Canada
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦Vancouver General Hospital, Vancouver, British Columbia, Canada
A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults
- Conditions
- First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- NoNO Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT05636306
- Locations
- 🇨🇦
Altasciences Company Inc., Mount Royal, Quebec, Canada
Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- NoNO Inc.
- Target Recruit Count
- 850
- Registration Number
- NCT04462536
- Locations
- 🇺🇸
St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States
🇺🇸Providence Little Company of Mary Medical Center - Torrance, Torrance, California, United States
🇺🇸Swedish Medical Center, Englewood, Colorado, United States
Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke
- First Posted Date
- 2016-10-11
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- NoNO Inc.
- Target Recruit Count
- 1105
- Registration Number
- NCT02930018
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸California Pacific Medical Center - Davies Campus, San Francisco, California, United States
🇺🇸Providence Little Company of Mary Medical Center Torrance, Torrance, California, United States
Field Randomization of Nerinetide (NA-1) Therapy in Early Responders
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- NoNO Inc.
- Target Recruit Count
- 532
- Registration Number
- NCT02315443
- Locations
- 🇨🇦
Kelowna General Hospital, Kelowna, British Columbia, Canada
🇨🇦Royal Columbian Hospital, New Westminster, British Columbia, Canada
🇨🇦British Columbia Ambulance Service and British Columbia Emergency Health Services, Vancouver, British Columbia, Canada
- Prev
- 1
- 2
- Next